Cagrilintide + Semaglutide (CagriSema)

Buy Cagrilintide + Semaglutide (CagriSema) Online

CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The combination is designed to influence complementary pathways involved in appetite, glucose regulation, and body-weight control.

Product Information

Cagrilintide acts on amylin receptors, while semaglutide activates GLP-1 receptors. Clinical development has evaluated the two compounds as a once-weekly fixed-dose combination, including phase 3 studies in obesity and type 2 diabetes.

How It Works

Semaglutide activates GLP-1 receptors involved in appetite and glucose regulation, while cagrilintide mimics amylin signaling involved in satiety and post-meal metabolic control. Their complementary mechanisms are intended to produce combined effects on energy intake and glucose metabolism.

POTENTIAL BENEFITS

1. Weight-Management Research

Phase 3 clinical research has demonstrated substantial body-weight reductions with once-weekly CagriSema. In REIMAGINE 1, the 2.4 mg + 2.4 mg combination produced a mean relative body-weight reduction of 13.8% at week 40 in adults with early-stage type 2 diabetes.

2. Glycemic-Control Research

CagriSema has been evaluated in people with type 2 diabetes, including participants receiving basal insulin. Recent phase 3 research demonstrated improved HbA1c compared with placebo and relevant comparator groups.

3. Appetite & Satiety Research

GLP-1 and amylin signaling both influence food intake and satiety. Combining these pathways provides a research model for studying multiple physiological signals controlling energy consumption.

4. Dual-Pathway Metabolic Research

CagriSema is particularly relevant to research examining whether complementary incretin and amylin signaling can produce broader metabolic effects than either pathway alone.

Dosage

Clinical trials have evaluated CagriSema using 1.0 mg + 1.0 mg and 2.4 mg + 2.4 mg weekly target doses, with dose escalation used during treatment. These are investigational trial regimens and should not be treated as an established general-use dosing protocol.

Side Effects

Gastrointestinal adverse events are among the most frequently reported effects in clinical studies. Recent phase 3 research reported nausea and other gastrointestinal disorders among the most common adverse events, consistent with the pharmacology of GLP-1 receptor agonism and previous cagrilintide data.

References

1. REIMAGINE 2 — Cagrilintide-semaglutide phase 3 trial, PubMed
2. REIMAGINE 3 — Cagrilintide-semaglutide phase 3 trial, PubMed
3. REIMAGINE 1 — Cagrilintide-semaglutide phase 3a trial, PubMed
4. CagriSema cardiovascular outcomes study — ClinicalTrials.gov
5. Cagrilintide and amylin-receptor research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.